Overview
- HSBC upgraded AbbVie to Buy on Dec. 10 and raised its price target to $265, followed by a Dec. 11 Seeking Alpha “Strong Buy” call.
- Q3 2025 results showed sharp gains: Skyrizi revenue reached about $4.7 billion (≈47% YoY) and Rinvoq hit $2.18 billion (≈35% YoY), with Humira at $993 million (≈55% YoY).
- Management projects Rinvoq at roughly $11 billion and Skyrizi at about $20 billion in 2027 sales, targets some analysts view as ambitious.
- The board increased the quarterly dividend 5.5% to $1.73 per share on Oct. 31, extending a multidecade record of annual raises.
- Coverage highlights patent protection into the 2030s for key assets and valuation support that includes a dividend yield around 3% and a lower forward P/E relative to peers.